Fig. 3From: Silencing HOXC13 exerts anti-prostate cancer effects by inducing DNA damage and activating cGAS/STING/IRF3 pathwayPrognostic characterization of 25 TFs in PCa. A Risk levels of 25 TFs in PCa. B OS of PCa patients with low (n = 249) and high (n = 249) HOXC13 expression (P = 0.048, HR = 1.52). C OS of PCa patients with low (n = 249) and high (n = 249) HOXC13 expression (P = 0.004, HR = 1.85)Back to article page